NCT02182531CompletedPhase 1
Study of the Pharmacokinetic Interactions and Relative Bioavailability of Epinastine and Pseudoephedrine in Healthy Volunteers, Comparing Tablets Containing the Fixed Combination of the Two Substances With Tablets Containing Each of the Two Substances Separately
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 25
- Primary Endpoint
- Index of the absorption rate Cpmax/AUCt (Peak plasma concentration/Area under the curve from zero to 24 hours)
Study Overview
Brief Summary
Study to compare the bioavailable fraction of epinastine and pseudoephedrine when administered as a fixed dose combination in tablet form (new pharmaceutical formulation), with that obtained with each of these drugs when administered separately to healthy volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy volunteers of both sexes aged between 21 and 45 years
- •Non-smoking volunteers
- •Volunteers willing to abstain from alcohol
- •The volunteers will have to have suspended any drug treatment at least two weeks prior to the start of the study
- •Informed consent in writing, signed in time for the start of the study
Exclusion Criteria
- •Women who are pregnant, breast-feeding or receiving hormonal contraceptives
- •Volunteers who require drug treatment of any kind of a chronic nature or due to a known addiction
- •Volunteers who have taken part in another clinical trial during the preceding four weeks
- •Volunteers who have to begin treatment incompatible with this one during the period of the present study (systemic anaesthetics by inhalation, antihypertensives or diuretics used as antihypertensives, beta-adrenergic blockers, CNS (central nervous system) stimulants, digitalis, glycosides, levodopa, monoamine oxidase inhibitors, nitrates, rauwolfia alkaloids, thyroid hormone sympathomimetics)
- •Volunteers who do not observe the fasting stipulated in the study or who do not satisfy its requirements with respect to avoiding the ingestion of coffee, tea, cola drinks, etc. during the 24 hours prior to the study
- •Volunteers with a history of hepatic or renal disease and disorders of psychiatric origin
- •A history of allergy or intolerance with respect to epinastine or pseudoephedrine
- •Volunteers who are intolerant of other sympathomimetics (e.g. salbutamol, amphetamine, ephedrine, etc.)
- •Non-cooperative volunteers
- •Previous participation in this study
- •Histories of cardiovascular disease, ischaemic heart disease, hypertension, diabetes mellitus, glaucoma, hyperthyroidism, prostatic hypertrophy
Arms & Interventions
Pseudoephedrine
Active Comparator
Intervention: Pseudoephedrine (Drug)
Pseudoephedrine
Active Comparator
Intervention: Epinastine + Pseudoephedrine combination (Drug)
Epinastine and Pseudoephedrine combination
Experimental
Intervention: Pseudoephedrine (Drug)
Epinastine and Pseudoephedrine combination
Experimental
Intervention: Epinastine + Pseudoephedrine combination (Drug)
Epinastine and Pseudoephedrine combination
Experimental
Intervention: Epinastine (Drug)
Epinastine
Active Comparator
Intervention: Epinastine (Drug)
Epinastine
Active Comparator
Intervention: Pseudoephedrine (Drug)
Epinastine
Active Comparator
Intervention: Epinastine + Pseudoephedrine combination (Drug)
Pseudoephedrine
Active Comparator
Intervention: Epinastine (Drug)
Outcomes
Primary Outcomes
Index of the absorption rate Cpmax/AUCt (Peak plasma concentration/Area under the curve from zero to 24 hours)
Time Frame: Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose
Area under the curve (AUC) of the analyte in plasma
Time Frame: Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose
Secondary Outcomes
- T1/2 (Drug half-life)(Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose)
- Number of withdrawals and discontinuations due to safety reasons(up to 15 days)
- Peak plasma concentration (Cpmax)(Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose)
- Tmax (Time to reach Cpmax)(Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose)
- Number of patients with adverse events(up to 15 days)
- Number of patients with clinically significant changes in vital signs(Baseline, day 1, 8, 15)
Investigators
Similar Trials
Completed
Not Applicable
Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part ATesticular cancerRetroperitoneal lymph node dissectionCancer - TesticularSurgery - Other surgeryACTRN12622000537752Peter MacCallum Cancer Centre52
Unknown
Not Applicable
Effects of Norepinephrine-ephedrine Combination on Maternal HemodynamicsCesareanNCT03672071Yuzuncu Yıl University90
Completed
Not Applicable
Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed ConditionsHealthyNCT00779805Ranbaxy Laboratories Limited40
Not yet recruiting
Unknown
Comparing the effect of Ephedrine and Phenylephrine infusion on hemodynamic stability after Spinal Anaesthesia in elderly patientsCTRI/2023/04/051451Shri B M Patil Medical College
Completed
Not Applicable
A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular EpinephrineAnaphylaxisNCT01432522Siriraj Hospital12